Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $141.00 short call and a strike $146.00 long call offers a potential 34.77% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $141.00 by expiration. The full premium credit of $1.29 would be kept by the premium seller. The risk of $3.71 would be incurred if the stock rose above the $146.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 27.93 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
AstraZeneca Gets Chile, Peru Nod To Resume COVID-19 Vaccine Trials
Thu, 05 Nov 2020 02:26:06 +0000
AstraZeneca plc (NYSE: AZN) has received the regulatory nod to conduct clinical trials of its COVID-19 vaccine in Chile and Peru, Reuters reported Wednesday.What Happened: Chile's President Sebastian Pinera said that his nation's health regulator had approved the British company's vaccine trial, according to Reuters.According to Pinera, the clinical trial of Johnson & Johnson (NYSE: JNJ) COVID-19 vaccine candidate is already underway and the doses of Sinovac's vaccine arrived in the country on Wednesday.Peru announced that trials of Johnson and Johnson and AstraZeneca vaccines would begin next week, according to Reuters. The country had withdrawn a deal to purchase AstraZeneca's vaccine two weeks ago as the company did not provide data on its vaccine studies. Why It Matters: Pinera also disclosed that Chile had signed up for 7.6 million doses of vaccine through the World Health Organization-led COVAX initiative.The World Bank is supporting COVAX and WHO's efforts and has pledged billion in financing for developing countries to purchase and distribute COVID-19 vaccines, tests, and treatments.The United Kingdom-based AstraZeneca already has deals for the production and supply of its COVID-19 vaccine with multiple Latin American countries.Price Action: AstraZeneca shares closed nearly 6.5% higher at $55.04 on Wednesday and gained 0.11% in the after-hours session.See more from Benzinga * Click here for options trades from Benzinga * B Bitcoin Linked To FBI-Seized Darknet Market Silk Road Is On The Move After 5 Years: Report * Trump Declares Victory Ahead Of Results From Key States(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Republican Hold On Senate Seen As Plus For Drug Companies
Wed, 04 Nov 2020 21:39:53 +0000
While the presidential race is undecided awaiting final results from key states, it appears Republicans could retain control of the Senate, and AbbVie stock and other biotech stocks rose.
Novavax Announces Covid-19 Vaccine Supply Deal With Australia
Wed, 04 Nov 2020 21:29:02 +0000
Novavax announced its latest Covid-19 vaccine deal, with Australia, and confirmed that it's on pace to release final-phase clinical trials data by the first quarter of 2021. NVAX stock rose.
Psychedelic Drug Stock Jumps After State Ballot Legalizes Therapy
Wed, 04 Nov 2020 21:17:21 +0000
Compass Pathways rallied after Oregon legalized psilocybin therapy and Washington, D.C., decriminalized the hallucinogenic substance.
Chilean president says regulators okay AstraZeneca COVID vaccine trial
Wed, 04 Nov 2020 20:42:26 +0000
Chilean President Sebastian Pinera said on Wednesday the country's health regulators had given the go-ahead to a clinical trial of the AstraZeneca PLC COVID-19 vaccine. Pinera said the AstraZeneca trial would follow one by America's Johnson & Johnson that is already underway and another by China's Sinovac, whose first vaccine doses arrived in Chile on Wednesday.
Also on Market Tamer…
Follow Us on Facebook